Form 4 Filing for BIOLARGO, INC.

This filing details a transaction by CODE KENNETH REAY, Chief Science Officer and Director of BIOLARGO, INC. On July 7, 2026, Mr. Reay acquired 532,567 shares of common stock at a price of $0.1135 per share. These shares were received in exchange for a reduction in owed salary and unreimbursed business expenses. The acquisition is subject to a lock-up agreement, restricting sales until the company achieves $40 million in gross revenue, a market capitalization of $300 million, or a change in control. This transaction results in a post-transaction ownership of 26,408,319 shares, including shares held indirectly through a wholly owned corporation. The filing also includes a Limited Power of Attorney authorizing John R. Browning to execute Section 16 reporting forms on behalf of Mr. Reay.